LevelJump Announces 2025 Third Quarter Results

Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and nine months ended September 30, 2025.

Financial and Operational Highlights

• Revenues were $4.84 million in the third quarter compared to $4.45 million in the same period the prior year, an increase of 8.7%.

• For the nine months ended September 30, 2025, revenues were $14.1 million compared to $12.9 million in the same period in 2024, an increase of 9.1%.

• Canadian Teleradiology Services, Inc., the Company's 100% owned subsidiary had EBITDA in the third quarter of $836,000.

• For the nine months ended September 30, 2025, Canadian Teleradiology Services, Inc. had EBITDA of $3.04 million.

2025 Third Quarter Financial Results

• Revenues of $4.85 million in the third quarter of 2025 with a net loss of $(26,378).

• EBITDA of $600,677 for the third quarter of 2025.

• Revenues of $14.1 million for the nine months ended September 30, 2025, with a net income of $5,754.

• EBITDA of $1.90 million for the nine months ended September 30, 2025.

Previously Announced Acquisition

The Company entered into an agreement to acquire two additional diagnostic imaging outpatient clinics located in Calgary, Alberta. The transaction was not approved by one of the vendors landlords and the transaction has been terminated. See the Company's news release dated June 13, 2025.

Management Comments

Mitch Geisler, CEO, commented, "We are very pleased with our Q3 results and year-over-year growth. We continue to focus on increasing clinic revenue with additional patients scans and other organic growth opportunities including our preparations in Alberta to add mammography and increase our fluoroscopy and pain management services."

Non-IFRS Financial Measures

This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.